Nature Reviews Immunology
10 January 2019
Volume: 19, 73-74
Several key papers published in 2018 that advance our understanding of resistance to chimeric antigen receptor (CAR) T cell immunotherapy for leukaemia and lymphoma and in so doing reveal barriers that must be addressed to increase efficacy of this novel class of therapeutics for B cell malignancies and expand their reach to solid tumours. Christine Brown and Crystal Mackall discuss the inroads to response and resistance.
Illustrator
